The most common adverse reactions reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving highly emetogenic chemotherapy were: hiccups (4.6% versus 2.9%), asthenia/ fatigue (2.9% versus 1.6%), alanine aminotransferase (ALT) increased (2.8% versus 1.5%), constipation (2.2% versus 2.0%), headache (2.2% versus 1.8%), and anorexia (2.0% versus 0.5%).
Väga emetogeenset kemoteraapiat saanud patsientidel olid kõige sagedasemad kõrvaltoimed, mille esinemissagedus oli suurem aprepitanti sisaldavat ravi kui standardravi saanud patsientidel: luksumine (4, 6% versus 2, 9%), asteenia/ väsimus (2, 9% versus 1, 6%), alaniini aminotransferaasi (ALAT) aktiivsuse suurenemine (2, 8% versus 1, 5%), kõhukinnisus (2, 2% versus 2, 0%), peavalu (2, 2% versus 1, 8%) ja isutus (2, 0% versus 0, 5%).